Key result
Anemia in chronic heart failure links to higher mortality, but ESAs lack convincing long-term safety.
This review highlights anemia as a common, multifactorial condition in chronic heart failure that serves as a significant prognostic marker for adverse outcomes.
Answers are grounded in this paper and cite their sources.
Anemia flags higher mortality risk in chronic HF; leaves open optimal correction strategies pending randomized safety data.
Anemia is common in patients with chronic heart failure (HF) with an incidence ranging from 4% to 55% depending on the studied population. Several studies have highlighted that the prevalence of anemia increases with worsening heart failure as reflected by New York Heart Association classification. Additionally, several epidemiological studies have highlighted its role as a prognostic marker, linking it to worse outcomes including; malnutrition, increased hospitalizations, refractory heart failure and death. The pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renal insufficiency. There are a host of epidemiological studies examining HF outcomes and anemia, but only a few randomized trials addressing this issue. The purpose of this article is to review the literature that examines the interrelationship of anemia and congestive HF, analyzing its etiology, impact on outcomes and also the role of associated kidney disease as well as cardiorenal syndrome both as a marker of morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
A 2010 study conducted a review in Anemia in chronic heart failure and cardiorenal syndrome. Erythropoiesis-stimulating agents (ESAs) and iron supplementation vs. Placebo or standard care without anemia correction was evaluated on Mortality and heart failure hospitalizations. Anemia affects 4% to 61% of chronic heart failure patients and is associated with increased mortality, while routine erythropoiesis-stimulating agent use lacks convincing long-term safety and efficacy data.
Synapse has enriched 10 related papers. Consider them for comparative context: